US Stock MarketDetailed Quotes
CRSP CRISPR Therapeutics
- 50.720
- +0.360+0.71%
Close Nov 6 16:00 ET
4.33BMarket Cap-18179P/E (TTM)
51.880High49.390Low2.28MVolume51.800Open50.360Pre Close114.77MTurnover2.72%Turnover RatioLossP/E (Static)85.35MShares91.10052wk High2.23P/B4.25BFloat Cap43.42052wk Low--Dividend TTM83.72MShs Float220.200Historical High--Div YieldTTM4.94%Amplitude11.630Historical Low50.396Avg Price1Lot Size
CRISPR Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -168.25%-106.91M | 28.27%-95.58M | 1,147.32%109.75M | 47.48%-260.38M | 15.23%-96.07M | 62.12%-39.86M | 6.14%-133.25M | 106.51%8.8M | -191.98%-495.74M | -31.72%-113.33M |
| Net income from continuing operations | 23.37%-85.94M | -62.60%-126.41M | -119.71%-116.59M | 76.37%-153.61M | 180.80%89.35M | 35.75%-112.15M | 58.17%-77.74M | 70.39%-53.07M | -272.16%-650.18M | 21.72%-110.58M |
| Depreciation and amortization | -3.78%4.74M | -2.34%4.85M | -4.32%4.83M | -17.93%19.84M | -16.18%4.9M | -1.85%4.93M | -31.75%4.96M | -16.36%5.05M | 34.64%24.17M | -6.63%5.85M |
| Other non cash items | -33.69%-6.9M | -159.63%-8.18M | -765.33%-8.39M | -212.63%-14.05M | -2,276.26%-4.77M | -299.96%-5.16M | -188.21%-3.15M | -115.89%-969K | -11.62%12.47M | -95.33%219K |
| Change In working capital | -176.78%-40.36M | 113.27%10.49M | 470.33%210.49M | -1,075.49%-193.59M | -545.02%-203.97M | 41.34%52.56M | -1,066.16%-79.08M | 505.53%36.91M | -26.11%19.85M | -271.01%-31.62M |
| -Change in receivables | --0 | --0 | --200M | -65,673.77%-200M | -408,263.27%-200M | 411,664.71%70M | -91,009.09%-70M | --0 | 289.44%305K | 132.03%49K |
| -Change in prepaid assets | -123.01%-188K | -39.98%2.35M | -75.51%2.95M | 1,353.00%23.22M | 218.05%6.45M | -83.76%817K | 251.69%3.91M | 161.11%12.04M | 111.49%1.6M | -212.36%-5.46M |
| -Change in payables and accrued expense | -54.53%-38.16M | 180.17%9.28M | -62.55%9.44M | -492.08%-20.25M | 70.44%-9.19M | -188.32%-24.69M | -216.72%-11.58M | 1,660.27%25.21M | -86.23%5.16M | -236.50%-31.1M |
| -Change in other current liabilities | 128.18%31K | 112.70%40K | -154.12%-432K | 107.23%110K | 7.80%705K | 89.29%-110K | 68.31%-315K | -10.39%-170K | 71.33%-1.52M | -44.48%654K |
| -Change in other working capital | -131.19%-2.04M | -7.18%-1.18M | -730.51%-1.47M | -76.69%3.33M | -145.76%-1.94M | 25.68%6.55M | -162.43%-1.1M | -105.72%-177K | 63.92%14.3M | 141.61%4.24M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -168.25%-106.91M | 28.27%-95.58M | 1,147.32%109.75M | 47.48%-260.38M | 15.23%-96.07M | 62.12%-39.86M | 6.14%-133.25M | 106.51%8.8M | -191.98%-495.74M | -31.72%-113.33M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -233.17%-161.6M | -158.50%-126.91M | -183.00%-97.8M | 244.84%374.65M | 53.60%-81.45M | 38.74%121.35M | 486.87%216.92M | 202.89%117.83M | 75.02%-258.66M | -1,913.91%-175.53M |
| Net PPE purchase and sale | 89.66%-219K | 80.11%-707K | 76.43%-721K | 74.53%-9.47M | 88.08%-738K | 64.80%-2.12M | 63.08%-3.56M | 80.07%-3.06M | 54.49%-37.19M | 32.58%-6.19M |
| Net intangibles purchase and sale | --0 | ---- | ---- | ---2.5M | --0 | ---1M | ---- | ---- | --0 | --0 |
| Net investment purchase and sale | -229.66%-161.39M | -156.85%-126.2M | -180.30%-97.08M | 274.57%386.62M | 52.34%-80.72M | 33.15%124.47M | 577.97%221.98M | 221.91%120.89M | 76.78%-221.47M | -36,361.46%-169.34M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -233.17%-161.6M | -158.50%-126.91M | -183.00%-97.8M | 244.84%374.65M | 53.60%-81.45M | 38.74%121.35M | 486.87%216.92M | 202.89%117.83M | 75.02%-258.66M | -1,913.91%-175.53M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 519.54%9.64M | -102.78%-466K | 5,561.25%305.93M | 62.38%62.66M | 1,471.39%38.94M | -89.70%1.56M | 61.93%16.77M | -49.25%5.4M | -84.62%38.59M | -60.66%2.48M |
| Net common stock issuance | --6M | ---1.01M | --280.75M | 3,273.30%32.72M | --32.72M | --0 | --0 | --0 | -99.55%970K | --0 |
| Proceeds from stock option exercised by employees | 133.74%3.64M | -96.74%546K | 366.12%25.19M | -20.41%29.94M | 150.93%6.22M | -89.00%1.56M | 61.93%16.77M | -49.25%5.4M | -0.15%37.62M | -60.66%2.48M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 519.54%9.64M | -102.78%-466K | 5,561.25%305.93M | 62.38%62.66M | 1,471.39%38.94M | -89.70%1.56M | 61.93%16.77M | -49.25%5.4M | -84.62%38.59M | -60.66%2.48M |
| Net cash flow | ||||||||||
| Beginning cash position | 8.63%495.99M | 101.88%718.94M | 79.00%401.07M | -76.16%224.06M | 5.74%539.6M | -11.01%456.6M | -49.18%356.12M | -76.16%224.06M | -20.71%939.94M | -50.38%510.33M |
| Current changes in cash | -411.72%-258.88M | -321.97%-222.95M | 140.76%317.89M | 124.72%176.94M | 51.61%-138.59M | 3,243.38%83.05M | 153.52%100.44M | 155.22%132.03M | -191.55%-715.8M | -223.76%-286.38M |
| Effect of exchange rate changes | 256.25%75K | -92.86%2K | -134.38%-11K | 191.25%73K | -46.96%61K | 52.00%-48K | 141.18%28K | 218.52%32K | -627.27%-80K | 3,733.33%115K |
| End cash Position | -56.04%237.19M | 8.63%495.99M | 101.88%718.94M | 79.00%401.07M | 79.00%401.07M | 5.74%539.6M | -11.01%456.6M | -49.18%356.12M | -76.16%224.06M | -76.16%224.06M |
| Free cash flow | -149.29%-107.13M | 30.38%-96.29M | 1,799.49%109.03M | 48.90%-272.35M | 19.00%-96.81M | 61.37%-42.97M | 8.76%-138.3M | 103.81%5.74M | -216.55%-532.93M | -25.52%-119.52M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
